Atomera Incorporated vs Quest Diagnostics Inc — how do they compare? Atomera Incorporated trades at $5.68 (market cap $217.36M), while Quest Diagnostics Inc trades at $236.94 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 120.6× Atomera Incorporated's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Atomera Incorporated pays none. Which is the better fit depends on your goals.
| ATOM | DGX | |
|---|---|---|
Market Cap | $217.36M | $26.21B |
Sector | Technology | Health |
52-Week High | $12.11 | $238.50 |
52-Week Low | $1.99 | $173.49 |
Enterprise Value | $180.18M | $31.97B |
Dividend Yield | — | 1.45% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Trailing returns across standard periods
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →